209 related articles for article (PubMed ID: 36383217)
1. Regulation of B cell receptor signalling by Epstein-Barr virus nuclear antigens.
Khasnis S; Veenstra H; McClellan MJ; Ojeniyi O; Wood CD; West MJ
Biochem J; 2022 Dec; 479(23):2395-2417. PubMed ID: 36383217
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
Wang A; Welch R; Zhao B; Ta T; Keleş S; Johannsen E
J Virol; 2015 Dec; 90(6):2906-19. PubMed ID: 26719268
[TBL] [Abstract][Full Text] [Related]
3. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
Pich D; Mrozek-Gorska P; Bouvet M; Sugimoto A; Akidil E; Grundhoff A; Hamperl S; Ling PD; Hammerschmidt W
mBio; 2019 Sep; 10(5):. PubMed ID: 31530670
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr Virus (EBV) Latent Protein EBNA3A Directly Targets and Silences the
Bazot Q; Paschos K; Allday MJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29367247
[TBL] [Abstract][Full Text] [Related]
5. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
[TBL] [Abstract][Full Text] [Related]
6. An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.
Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Zumwalde NA; Bristol JA; Nelson SE; Ma S; Ranheim EA; Gumperz JE; Johannsen EC; Kenney SC
J Virol; 2020 May; 94(10):. PubMed ID: 32132242
[TBL] [Abstract][Full Text] [Related]
7. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
[TBL] [Abstract][Full Text] [Related]
8. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa).
Robertson ES; Lin J; Kieff E
J Virol; 1996 May; 70(5):3068-74. PubMed ID: 8627785
[TBL] [Abstract][Full Text] [Related]
9. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
Schlee M; Krug T; Gires O; Zeidler R; Hammerschmidt W; Mailhammer R; Laux G; Sauer G; Lovric J; Bornkamm GW
J Virol; 2004 Apr; 78(8):3941-52. PubMed ID: 15047810
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes.
Schmidt SC; Jiang S; Zhou H; Willox B; Holthaus AM; Kharchenko PV; Johannsen EC; Kieff E; Zhao B
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):554-9. PubMed ID: 25540416
[TBL] [Abstract][Full Text] [Related]
11. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
[TBL] [Abstract][Full Text] [Related]
12. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
[TBL] [Abstract][Full Text] [Related]
13. The EBNA3 Family: Two Oncoproteins and a Tumour Suppressor that Are Central to the Biology of EBV in B Cells.
Allday MJ; Bazot Q; White RE
Curr Top Microbiol Immunol; 2015; 391():61-117. PubMed ID: 26428372
[TBL] [Abstract][Full Text] [Related]
14. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
Schlager S; Speck SH; Woisetschläger M
J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional repression by the Epstein-Barr virus EBNA3A protein tethered to DNA does not require RBP-Jkappa.
Bourillot PY; Waltzer L; Sergeant A; Manet E
J Gen Virol; 1998 Feb; 79 ( Pt 2)():363-70. PubMed ID: 9472621
[TBL] [Abstract][Full Text] [Related]
16. EBNA2 and Its Coactivator EBNA-LP.
Kempkes B; Ling PD
Curr Top Microbiol Immunol; 2015; 391():35-59. PubMed ID: 26428371
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus latent gene sequences as geographical markers of viral origin: unique EBNA3 gene signatures identify Japanese viruses as distinct members of the Asian virus family.
Sawada A; Croom-Carter D; Kondo O; Yasui M; Koyama-Sato M; Inoue M; Kawa K; Rickinson AB; Tierney RJ
J Gen Virol; 2011 May; 92(Pt 5):1032-1043. PubMed ID: 21248177
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA.
Waltzer L; Perricaudet M; Sergeant A; Manet E
J Virol; 1996 Sep; 70(9):5909-15. PubMed ID: 8709211
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.
Kelly GL; Milner AE; Tierney RJ; Croom-Carter DS; Altmann M; Hammerschmidt W; Bell AI; Rickinson AB
J Virol; 2005 Aug; 79(16):10709-17. PubMed ID: 16051863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
